Edaravone protects against ischemia/reperfusion-induced functional and biochemical changes in rat urinary bladder

Matsumoto, Seiji; Hanai, Tadashi; Yoshioka, Nobuhiro; Shimizu, Nobuyoshi; Sugiyama, Takahide; Uemura, Hirotsugu; Levin, Robert M.

doi:10.1016/j.urology.2005.04.035

Cited by 28 publications

(22 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In rats, edaravone was reported to protect the contractile responses to field stimulation and carbachol, as well as reduce MDA content following I/R-induced damage to the bladder (83).…”

Section: Bladder Injurymentioning

confidence: 99%

Beyond neurological disease: New targets for edaravone (Review)

Kikuchi¹,

Uchikado²,

Miyagi³

et al. 2011

Int J Mol Med

View full text Add to dashboard Cite

show abstract

“…In rats, edaravone was reported to protect the contractile responses to field stimulation and carbachol, as well as reduce MDA content following I/R-induced damage to the bladder (83).…”

Section: Bladder Injurymentioning

confidence: 99%

Beyond neurological disease: New targets for edaravone (Review)

Kikuchi¹,

Uchikado²,

Miyagi³

et al. 2011

Int J Mol Med

View full text Add to dashboard Cite

show abstract

“…CP-induced cystitis is caused by the metabolite acrolein, which rapidly enters into the urothelial cells and produces ROS, and is prevented by ROS scavengers or antioxidants (13, 20 -22). It is suggested that bladder dysfunction induced by bladder outlet obstruction (23,24) and ischemia/reperfusion (25,26) are due to the generation of ROS. In addition, ROS are abundantly produced by infiltrated inflammatory cells such as macrophages, neutrophils, and mast cells in the inflamed bladder (27 -29).…”

mentioning

confidence: 99%

A Novel Mouse Model of Chronic Inflammatory and Overactive Bladder by a Single Intravesical Injection of Hydrogen Peroxide

et al. 2013

View full text Add to dashboard Cite

“…Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-1; norphenazone; MCI-186), a potent scavenger of hydroxyl and peroxyl radicals, inhibits lipid peroxidation via its antioxidant activity. Animal studies on the mitigation of small intestine damage found that edaravone decreases the degree of I-R-mediated mucosal tissue injury [5][6][7]. Elsewhere, we showed that, in a rabbit ASMAT model that introduced autologous fibrin clots, thrombolysis via the intra-arterial administration of edaravone and urokinase contributed to a reduction in the degree of I-R injury to the small intestinal mucosa [4].…”

mentioning

confidence: 57%

Does the concomitant intra-arterial injection of asialoerythropoietin and edaravone mitigate ischaemic mucosal damage after acute superior mesenteric artery thromboembolism in a rabbit autologous fibrin clot model?

Sonoda

Nitta²,

Seko³

et al. 2010

BJR

View full text Add to dashboard Cite

ABSTRACT. To increase the survival rate of patients with acute superior mesenteric artery thromboembolism (ASMAT) treated by catheter thrombolysis, we examined the effects of delivering edaravone and asialoerythropoietin, agents with tissue-protective activities, using a rabbit autologous fibrin clot ASMAT model. Japanese white rabbits (n532) were randomly separated into four equal groups. 45 min after introducing autologous fibrin clot, Group U received urokinase and heparin; Group E received urokinase and heparin plus edaravone; Group A received urokinase and heparin plus asialoerythropoietin; and Group EA received urokinase, heparin and edaravone plus asialoerythropoietin via a catheter. The intestines were removed 6 h later and intestinal mucosal damage was scored using the Park's injury score. Survival time was assessed. Average mucosal injury was 5.78¡1.52 (Group U), 2.88¡0.72 (Group E), 1.90¡1.23 (Group A) and 1.18¡1.25 (Group EA). The degree of mucosal injury was significantly lower in Group EA than in Groups U and E (p,0.05). Conversely, there was no significant difference between Group A and Group EA, or between Group A and Group E. The survival times were 31.50¡13.30 h (Group U), 51.00¡24.74 h (Group E), 48.00¡16.97 h (Group A) and 82¡51.07 h (Group EA); the difference among the four groups was not significant. In conclusion, the concomitant administration of asialoerythropoietin and edaravone reduced mucosal membrane injury significantly compared with edaravone alone. However, to improve the survival of ASMAT rabbit models, the delivery of an appropriate dose of asialoerythropoietin is required, together with the development of methods to assess peripheral recanalisation.

show abstract

Edaravone protects against ischemia/reperfusion-induced functional and biochemical changes in rat urinary bladder

Cited by 28 publications

References 14 publications

Beyond neurological disease: New targets for edaravone (Review)

Beyond neurological disease: New targets for edaravone (Review)

A Novel Mouse Model of Chronic Inflammatory and Overactive Bladder by a Single Intravesical Injection of Hydrogen Peroxide

Does the concomitant intra-arterial injection of asialoerythropoietin and edaravone mitigate ischaemic mucosal damage after acute superior mesenteric artery thromboembolism in a rabbit autologous fibrin clot model?

Contact Info

Product

Resources

About